Abstract: The invention is directed to compounds and methods for prevention and/or treatment of inflammation using the same.

Abstract: The present invention is directed to methods for treatment and/or prevention of a disease associated with vascular leak in a patient comprising administering to the patient an effective amount of SEQ ID NO: 1.

Abstract: Peptides, peptidomimetics and derivatives thereof of the following general formula I: (SEQ ID NO: 1) (I) H2N-GHRPX1X2X3-?-X4X5X6X7X8X9X10-X11, in which X1-X10 denote one of the 20 genetically coded amino acids, wherein X8, X9 and X10 individually or jointly may also denote a single chemical bond X11 denotes OR1 in which R1 equals hydrogen or (C1-C10)alkyl NR2R3 with R2 and R3 are equal or different and denote hydrogen, (C1-C10)alkyl or a residue —W-PEG5-60K, in which the PEG residue is attached via a suitable spacer W to the N-atom, or a residue NH—Y-Z-PEG5-60K, in which Y denotes a single chemical bond or a genetically coded amino acids from the group S, C, K or R and in which Z denotes a spacer, via which a polyethylene glycol (PEG)-residue can be attached, as well as their physiologically acceptable salts, and in which additionally ? denotes an amino acid, whether genetically coded or not, or a peptidomimetic element, which have the additional property of inducing a bend or

Abstract: Peptides and peptide derivatives of the following general Formula I: (SEQ ID NO: 15) (I) H2N-GHRPX1X2X3X4X5X6X7X8PX9X10X11PX12PPPX13X14X15 X16GYR-X17, wherein: X1-X16 denote one of the 20 genetically encoded amino acids, X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen, (C1-C10)-alkyl, or a residue -PEG5-60K, wherein the PEG-residue is linked to the N atom via a spacer, or a residue NH—Y-Z-PEG5-60K, wherein Y denotes a chemical bond or a genetically coded amino acid from among the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may be linked, as well as the physiologically acceptable salts thereof, or wherein: X15 or X16 denotes an amino acid from the group of C or K, which is linked to a residue Z-PEG5-60K via the heteroatom in the side chain, and wherein X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or

Abstract: Peptides and derivatives thereof of the following general formula I: (SEQ ID NO: 1) (I) H2N-GHRPX1X2PX3X4X5PX6PPPX7X8X9X10B(1)B(2)B(3)- X11, wherein: B(1) denotes either a chemical bond or the amino acid G B(2) denotes either a chemical bond or the amino acid Y B(3) denotes either a chemical bond or the amino acid R X1—X10 denote one of the 20 genetically encoded amino acids, X11 denotes OR1 with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen, (C1-C10)-alkyl or a residue -PEG5-60K, wherein the PEG-residue is linked to the N atom via a spacer, or a residue NH—Y-Z-PEG5-60K, wherein Y denotes a chemical bond or a genetically coded amino acid from among the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may be linked, as well as the physiologically acceptable salts thereof.

Abstract: A method screens compounds out of the group consisting of proteins, peptides, peptidomimetics, antibodies and small organic molecules that increase the activity of the protein Rac1 by virtue of their binding to the extracellular portion of this protein. The method includes the steps of: contacting a confluent layer of cultured endothelial cells with at least one of test compounds, lysing the endothelial cells with a lysation buffer, and measuring the amount of Rac1 activity.